Vertex to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, January 29
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NAS: VRTX) will report its fourth quarter and full year 2012 financial results on Tuesday, January 29, 2013 after the financial markets close. The company will host a conference call at 5:00 p.m. ET.
The conference call will be webcast live and a link to the webcast may be accessed from the "Vertex Events" page of Vertex's website at www.vrtx.com. A replay of the conference call and webcast will be archived on the company's website until February 5, 2013. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, Mass., we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada. Today, Vertex has more than 2,000 employees around the world, and for three years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. Vertex's press releases are available at www.vrtx.com.
Vertex Pharmaceuticals Incorporated
Kate Carlson, 617-341-6668
KEYWORDS: United States North America Massachusetts
The article Vertex to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, January 29 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.